A new formulation of bevacizumab, Lytenava, raises pricing concerns for repurposed drugs, with researchers suggesting lower cost ranges.
2
Bevacizumab, originally for cancer, is widely used off-label for retinal diseases due to its lower cost compared to approved alternatives.
3
Researchers propose a sustainable price range of €73 to €177 per injection for repurposed bevacizumab, significantly lower than current prices.
4
The study emphasizes the need for transparency in cost structures to facilitate balanced pricing discussions between manufacturers and payers.
5
Current pricing dynamics for repurposed drugs may hinder investment while imposing high costs on healthcare systems, necessitating better pricing models.
